Opthea (OPT) announced the completion of its drug product Process Performance Qualification campaign for sozinibercept. The PPQ campaign consisted of the successful production of three consecutive commercial-scale drug product batches required to further validate Opthea’s manufacturing process in preparation for a potential biologics license application filing and commercialization of sozinibercept in wet AMD. The batches have been produced subsequent to the successful completion of the drug substance PPQ campaign announced in September 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPT:
- Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position
- Opthea completes COAST final week 52 patient visit
- Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment
- Opthea Unveils Promising Wet AMD Therapy at Investor Day
- Opthea’s Innovative Approach to AMD Treatment with Sozinibercept